By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
The Catalyst MagazineThe Catalyst Magazine
Notification Show More
Latest News
Tottenham Hotspur Vs Arsenal (0 – 2) On 15th January 2023
SPORT
Chelsea Vs Crystal Palace (1 – 0) On 15th January 2023
SPORT
Big Brother Titans Starts 7pm Today, All You Need To Know And How To Watch
ENTERTAINMENT
Stop These Sexual Acts In 2023
LIFESTYLE
Kunle Afolayan’s ‘Anikulapo’ Tops Most Watched Movies On Netflix Naija 2022 
ENTERTAINMENT
Aa
  • Home
  • News
    • POLITICS
    • TECH
    • SPORT
    • ENTERTAINMENT
    • BUSINESS
    • LIFESTYLE
    • HEALTH
  • Magazines
  • Contact
Reading: Vaccine production, Nigeria’s rocket science
Share
Aa
The Catalyst MagazineThe Catalyst Magazine
Search
  • Home
  • News
    • POLITICS
    • TECH
    • SPORT
    • ENTERTAINMENT
    • BUSINESS
    • LIFESTYLE
    • HEALTH
  • Magazines
  • Contact
Have an existing account? Sign In
Follow US
The Catalyst Magazine > Blog > HEALTH > Vaccine production, Nigeria’s rocket science
HEALTH

Vaccine production, Nigeria’s rocket science

admin
Last updated: 2021/05/25 at 3:05 PM
admin Published May 25, 2021
Share
SHARE

Biovaccines

Sixteen years after the Federal Government and May & Baker Nigeria Plc incorporated Biovaccines Nigeria Limited as the special-purpose vehicle to revive vaccine production locally, it has yet to deliver on its mandate. YUSUFF MOSHOOD reports

Biovaccines Nigeria Limited was incorporated in 2005 as a special firm to revive vaccine production activity in Nigeria, being a joint venture between the Federal Government and May & Baker Nigeria Plc.

While May & Baker owns 51 percent of the company, the Federal Government owns the remaining 49 percent of its shareholding.

The expectation when BVNL was established in 2005 was that it would leverage on the strength of May & Baker– its parent company and Nigeria’s first pharmaceutical firm –to end the long wait for locally-manufactured vaccines.

“The objective of Biovaccines Nigeria Limited is to produce safe and affordable human vaccines for Nigeria and reverse the situation of high mortality from immunisable diseases. It also plans to create a regional centre for vaccine production in West Africa and position Nigeria as a global player in the vaccine business,” its corporate bio states.

However, 16 years after, BVNL is yet to deliver on its grand objective.

 What went wrong

According to PUNCH HealthWise findings, the 2005 joint venture agreement between the FG and May & Baker concerning BVNL’s operations broke down and was only revived in 2017 when a new Memorandum of Understanding vetted by the Federal Executive Council was signed.

The signing of the MoU in 2017 also led to the inauguration of the Board of Directors for BVNL. It was a seven-member board, with three members from the government, while the other four members who will run the company are designates of May & Baker.

According to the MoU, Biovaccines Nigeria Limited is mandated to build local capacity in vaccine manufacturing, develop a research and development centre for vaccines and roll out the first locally produced vaccines by 2019.

The immediate focus was the production of yellow fever, tetanus and hepatitis B vaccines, all of which have remained a pipe-dream so far.

The company is also expected to revive the moribund Federal Vaccine Production Laboratory in Yaba, Lagos, which it acquired under the agreement.It’s been four years since the MoU was signed, yet there is no locally-made vaccine, either by the BVNL or any local entity for that matter.

Visit to Biovaccines Nigeria Limited

A visit to BVNL facility in Yaba, Lagos, indicated that work was ongoing there.However, a request by our correspondent to be taken on a tour of the facility was turned down.

The Chief Operating Officer of the company, Mr. Everest Okeakpu, told our correspondent to come with a formal letter of request, stating the objectives of the visit before an appointment could be fixed.

Nigeria’s frustrating history of vaccine production

It could be recalled that Nigeria was producing vaccines for smallpox, yellow fever and some anti-rabies between 1940 and 1991 and had even exported some vaccines to some African countries.

Vaccine production, however, stopped in 1991 at the Federal Vaccine Production Laboratory in Yaba, with the Federal Government stating that it would upgrade the facility. Since then, there has not been human vaccine manufacturing in Nigeria.

Nigeria, therefore, spends billions of naira annually to import vaccines, even though the Global Vaccine Initiative subsidises the cost heavily.

BVNL’s first set of vaccines expected in four years

Speaking with PUNCH HealthWise, BVNL’s COO, Okeakpu, said that Biovaccines Nigeria Limited was on track to deliver on its mandate despite its numerous challenges, noting that the company should be able to manufacture its first set of vaccines in the next four years.

“It usually takes about three to four years to go through facility construction and equipment procurement; facility and equipment installation, commissioning and qualification; process optimisation and validation; facility certification; process validation and product registration.

“The Biovaccines Nigeria Limited Joint Venture Agreement was ratified by the Federal Executive Council of the President Muhammadu Buhari-led administration at its June 8, 2017, meeting.

“The BVNL board swiftly set to work after re-inauguration in January 2018 with the first task of approving the strategic business plan that had been developed following very extensive feasibility studies.

“We commenced interactions with several international potential technology transfer partners and also issued two Request for Proposals,” Okeakpu said.

Continuing, the COO said, “The first Request for Proposals was for vaccines manufacturing technology from vaccines manufacturers for innovative technologies to manufacture Nigeria’s vaccines of interest — BCG vaccine, inactivated polio vaccine (IPV), Human Papillomavirus Vaccine (HPV), yellow fever vaccine (YFV), Hepatitis B vaccine (HBV), and Measles-Rubella Vaccine (MRV).

“Others are Pentavalent Vaccine (Diphtheria, Tetanus, Whole-Cell Pertussis, Hepatitis B, Hib), Pneumococcal Conjugate Vaccine (PCV), Tetanus Reduced Diphtheria (Td), Meningococcal Conjugate Vaccine (MCV) and Rotavirus Vaccine (RVV).

“Evaluation of the received proposals have since been concluded and technology partners shortlisted and selected.

“Request for Proposals two, which was for architectural, structural, conceptual basic and detailed engineering services was also launched shortly afterward.

“The Biovaccines Nigeria Limited facility will be compliant with the most stringent regulatory requirements, enable ease of future expansion, as well as ensure sustainability from a market competitiveness perspective.”

Okeakpu said that it became necessary to revise the BVNL strategic business plan earlier approved by the board when, on June 7, 2018, Gavi Board approved exceptional support for Nigeria up till 2028.

“Nigeria was due for transition out of Gavi support in 2021, and the BVNL strategic business plan was premised on this.However, following the revised GAVI transition plan (2018-2028) for Nigeria, the board approached the government for the details of the plan and has promptly revised the BVNL business plan to align with the new projection.

“Indeed, the implementation of the new plan is well underway. Talks have advanced and MoUs for Tech Transfer are already in place. We are currently engaging other strategic partners for collaboration and support.”

BVNL’s Achilles’ heel

Okeakpu also stated that the company has recently approved a company to undertake the architectural, structural, conceptual basic and detailed engineering design study of the Biovaccines Nigeria Limited Greenfield Integrated Biotech Park.

“Procurement for a suitably qualified local environmental consulting firm has also been concluded and the Environmental Impact Assessment study is currently ongoing at the 15.3-hectare piece of property procured for this purpose

You Might Also Like

COVID-19: Vaccination Not Compulsory For Civil Servants – FG

UPDATED: WHO approves China’s Sinovac Covid vaccine

‘Infertile women abusing ovulation-inducing drugs risk diabetes, cardiovascular diseases’

UK approves single shot Johnson & Johnson COVID-19 vaccine

COVID-19: Ondo warns residents against non-compliance with safety measures

admin May 25, 2021
Share this Article
Facebook Twitter Email Print
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Follow US

Find US on Social Medias
Facebook Like
Twitter Follow
Youtube Subscribe
Telegram Follow

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!

[mc4wp_form]
Popular News

UPDATED: Flags fly at half-mast at TB Joshua’s church, as worshippers wail, mourn

admin admin June 7, 2021
CBN Disburses ₦45 Billion To Lagos For Blue Line Railway Project
Why breast milk quality varies among nursing mothers, according to paediatricians
Experts carpet CBN, say serial naira devaluation threatens economy, Nigerians
How to check IMEI number for mobile device
- Advertisement -
Ad imageAd image
Global Coronavirus Cases

Confirmed

0

Death

0

More Information:Covid-19 Statistics

Categories

  • ES Money
  • U.K News
  • The Escapist
  • Insider
  • Science
  • Technology
  • LifeStyle
  • Marketing

About US

We influence 20 million users and is the number one business and technology news network on the planet.
Quick Link
  • My Bookmark
  • Interests
  • Contact Us
  • Blog Index
Top Categories
  • My Bookmark
  • Interests
  • Contact Us
  • Blog Index

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

[mc4wp_form]

© Foxiz News Network. Ruby Design Company. All Rights Reserved.

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?